News

Aurobindo‘s Alprazolam Extended-Release Tablets 0.5mg, 1mg, 2mg, and 3mg are generic equivalent to Pharmacia and Upjohn’s Xanax XR tablets 0.5mg, 1mg, 2mg, and 3mg. Alprazolam Extended-Release Tablets are

Emtrix exhibits mechanism of action in which visible improvements are seen within 2-4 weeks of treatment. Under the agreement OzHealth Pharma will receive rights to market and sell

The thermal insulation is used in the ultra low temperature Cryometrix T-150 freezers that Reflect Scientific manufactures and sells. Reflect Scientific develops technologies in cryogenic cooling for the

The study has been conducted by the Microdose’s collaborators at the University of Pittsburgh with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI). The Phase

NKTR-181, a mu-opioid analgesic investigational drug candidate, was created using Nektar’s small molecule polymer conjugate technology. The Phase 1 study is assessing the pharmacokinetics, pharmacology, safety and efficacy

The products to be developed by the company are in-licensed and own products and the larger focus is on self-researched products. Elder Pharmaceuticals director Alok Saxena said they

The NDA, submitted on 7 April 2011, includes data from two randomized double blind phase 3 clinical trials that compared 0.5% ivermectin cream with a vehicle control (placebo).

As per the terms of the agreement, Affectis Pharma will license exclusive rights to Merck for the development and commercialization of the proposed compounds. Affectis Pharma is entitled

Developed by GW Pharmaceuticals, Sativex (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) is in phase III clinical development for the treatment of cancer pain, as the next indication following MS